Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx (@OncLive)

Congrats to @ASCO @jrgralow & the co-PIs on PCORI award. This clinical trial aims to improve care of older patients with metastatic breast cancer with CDK4/6 I. It builds ASCO’s commitment to health equity by ensuring all patients benefit from advances made in cancer treatment. (@ASCOPres)

A new @ASCO study, co-led by the HICCC's Dr. Dawn Hershman (@DrDawnHershman) has been awarded $11 million in research funding by @PCORI to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. @ColumbiaMed https://t.co/wQCQAVjBg7 (@columbiacancer)

Incredibly excited for this opportunity with support from @PCORI to study how we can help older patients with metastatic breast cancer better tolerate therapy w/ CDK4/6 inhibitors, & stay on treatment longer. @ASCO @DrDawnHershman @elmayermd @LGM_Biostats https://t.co/oGe5Fs9yQI (@jrgralow)

Today @PCORI awarded $11M to @ASCO to study CDK4/6 inhibitor dosing in older patients w/metastatic breast cancer. Despite BC being more prevalent in people <65, few are included in current CDK4/6 trials. Study will be co-led by @elmayermd @DFCI_BreastOnc https://t.co/YYKIlCDYvf (@DanaFarberNews)

We’re pleased to announce ASCO has been awarded $11M of @PCORI research funding to study CDK4/6 inhibitors dosing in older adults w metastatic breast cancer. Led by our CMO @jrgralow, the aim is to improve outcomes & fill a real-world evidence gap. More: https://t.co/iNfEyf3G1G (@ASCO)

Congratulations @ASCO ! This is a patient-centered look at treatment of older adults with #MetBreastCancer with CDK4/6 inhibitors. #TeamScience #PatientVoice @JaniceTNBCmets @TPollastro @jrgralow @DrDawnHershman @elmayermd (@paspears88)

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in HR-positive breast cancer, the future of ADCs in TNBC, and the importance of a shared decision-making process in breast cancer treatment. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/eAR3QZt7Pa (@OncLive)

@IUCancerCenter ASCO 23 review continues with @TarahBallinger taking us on a tour through different ERAS of CDK4/6i in breast cancer (love the @taylorswift13 ref) (@anita_turk)

Awesome talk by Dr. @DrRanaMcKay on the future perspectives of new drugs and compounds in RCC, highlighting antibody drug conjugates, radio pharmaceutical agents, PARP inhibitors and CDK4/6 inhibitors. #KCRS23 @OncoAlert (@FabioSchutz78)

Selection and sequencing of CDK4/6 inhibitors in metastatic HR+/HER2- breast cancer hinge on the maturation of data in the first-line setting and beyond, and need to account for patient concerns and preferences. @drsarahsam @DanaFarber #bcsm #oncology https://t.co/SxrWSHh8F9 (@OncLive)

Dr McDermott discussing LOTESPARK-024 Belzutifan +/- Palbociclib in RCC hoping it’s “the next big thing coming out of ⁦@kaelin_lab⁩” #kcrs23 ⁦@kidneycan⁩ (@MosheOrnsteinMD)

Join Dr. Tolaney (@stolaney1) for a live virtual roundtable on August 8th on Implementing Guideline Recommendations for CDK 4/6 Inhibition in Early #BreastCancer. Register today and submit your questions to the panel: https://t.co/OWcM05JbP8 @Medthority https://t.co/IbSqV6MOCr (@DFCI_BreastOnc)

Listen to a discussion between the Oncology Brothers and Stephanie Graff, MD, FACP, on the role of CDK4/6 inhibition with aromatase inhibitor therapy following data from the SONIA trial in HR+ metastatic breast cancer. #bcsm | @OncBrothers @DrSGraff https://t.co/DaR4DpvQqf (@TargetedOnc)

Our novel finding on distinct mechanisms of resistance to palbociclib and abemaciclib in HR+ / HER2- MBC. Is there rationale for switching CDK4/6i after progression? @kandymarsy @KellyKhunt @MDAndersonNews @CR_AACR @HarmonyTurk https://t.co/BMmXIlJ3kt (@kandymarsy)

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer @drsarahsam @DanaFarber @OncLiveSOSS #bcsm #oncology https://t.co/TXArfvn893 (@OncLive)

🎥@ErikaHamilton9 from @SarahCannonDocs discusses age-related results in adjuvant abemaciclib + endocrine therapy for high-risk early #BreastCancer. Patients ≥65 had similar survival, safety, and dose reduction possibilities: ➡️https://t.co/ytt8RDV8Be⬅️ #BCSM #ASCO23 @ASCO (@VJOncology)

What is the best strategy after CDK4/6 inhibitors for the treatment of HR+ breast cancer? We need high quality #RWE to address important questions that will not be answered by RCTs @DMBranco presenting the #ALINE study proposal for the @oncodistinct network @OncoAlert #bcsm (@Nader_Guilherme)

Sharing our most recent research paper on the effectiveness of palbociclib with aromatase inhibitors for advancer #breastcancer. IPOLisboa Faculdade de Farmácia da Universidade de Lisboa INFARMED, I.P. @DMBranco @ajrsferreira joint…https://t.co/C4xDFOKAi3 https://t.co/Nat0arMnK7 (@Filipa_A_C)

2/6 #TumorBoardTuesday ThursCase🎀 Take🏠msgs: #metastatic HR+ #breastcancer ✅ NGS is 🗝️ in ER+ mBC on CDK4/6i ✅ ESR1 mut➡️Elacestrant ✅ No ESR1 mutation, but PIK3CA mut, consider 🎯tx, beware side effects 📚Here’s @ilanaschlam @drsarahsam’s thread https://t.co/DcA8w8ofI9 (@JohnEbbenMDPhD)

@stolaney1, ASCO 2023💫: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer. https://t.co/L7sdlObWex (@DFCI_BreastOnc)

3/17 #TumorBoardTuesday #BCSM @DrGattiMays @KalinskyKevin @chibaAkiko @stage4kelly @hmcarthur Keeping the 👆🏽above 👩 patient in mind. 🤔 Would you consider the continuation of CDK4/6 inhibition with a different endocrine therapy backbone? ♻️ (@IlanaSchlam)

11/17 #TumorBoardTuesday #SABCS22 ✨EMERALD✨ post hoc analysis: ❗without ESR1 mutations + PD <6mos on CDK4/6 inhibitor = elacestrant ⬆️ PFS (5.3 vs 1.9m) ❗without ESR1 mutations + PD >6mos on CDK4/6 inhibitor = elacestrant ↔️ PFS (1.9 vs 2 m) #ASCO23 #VirginiaKalkamani (@IlanaSchlam)

It's time! #TumorBoardTuesday starting up NOW. Follow along as @IlanaSchlam & @drsarahsam discuss post-CDK4/6i treatment options in metastatic breast cancer and some #ASCO23 highlights! @marina_sharifi (@JohnEbbenMDPhD)

#SABCS22 & #ASCO23 brought more study data &💥developments💥 in #BreastCancer 💥Join @IlanaSchlam @drsarahsam Tues 06.27.23 at 8pm ET as they 🗣️ to help #TumorBoardTuesday disseminate more about tx for patients while on a CDK4/6i 💥Earn CME @DFCI_BreastOnc @TuftsMedicalCtr (@TumorBoardTues)

💥#ASCO23 had tx developments for #BreastCancer! 💥Tuesday 06.27.23 at 8pm ET @ilanaschlam @drsarahsam take us through 2L+ tx opts on a CDK4/6i 💬Join us here on #TumorBoardTuesday! 🧠While we finalize the case, collect FREE #CME 👉🏽https://t.co/7qt1D9Jc0c👈🏼 #OncTwitter #BCSM (@TumorBoardTues)

5/5 #TumorBoardTuesday Case🎀 🎯Biomarkers increasingly informing best tx options in #GIST and many other cancers. ➡️Mark your calendar for Tuesday 06/27 when @ilanaschlam @drsarahsam discuss #BreastCancer progression on a CDK4/6i & #ASCO23 updates! (@JohnEbbenMDPhD)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/Hpc5ZFF5GJ (@OncLive)

📢Our new paper is out! Fecal microbiota composition is related to response to CDK4/6-inhibitors+ET in HR+/HER2- metastatic #breastcancer https://t.co/qSzLlKKVKC Thanks to #DanieleGenerali @curijoey @valerioiebba and all the team involved. Here the results in brief 👇🏻 (@FrancescoSche20)

Thank you 🙏🏼 for an outstanding and beneficial walk through #GIST on #TumorBoardTuesday!! Look for Case Wrap Up 🎀 Thursday 06/22/23 📅Please mark your calendar for Tuesday 06/27 when @ilanaschlam @drsarahsam discuss #BreastCancer progression on a CDK4/6i & #ASCO23 updates (@TumorBoardTues)

Gedatolisib + palbociclib & letrozole produced durable responses w/ comparable safety to that observed w/ palbociclib & letrozole alone in treatment-naïve patients withER-positive, HER2-negative advanced breast cancer @hoperugo @UCSFCancer #bcsm https://t.co/D5Xk9qw1X0 (@OncLive)

CDK4/6i, ADCs & more in early and metastatic breast cancer @ASCO. The #high5oncologyTV experts discuss the data: https://t.co/an34reB0a4 @evaciruelos @JavierCortesMD @CarmenCriscit @curijoey @AgoStudy @ALEDIGNUS12 @Dlueftner @volkmar_mueller @BarbaraPistill2 @hoperugo @stolaney1 (@high5md)

all the metastatic hormone positive her2 negative breast cancers don’t benefit from CDK4/6 inhibitors in front line! Speaker: Barbara Pistilli #florencebreast23 @OncoAlert @acampsmalea @ChelainG @MartaPerachino @FatjonaKrajaMD @FrancicaPaola (@Dr_m_garousi)

Stay tuned ! 🙌 First session : CDK 4/6 inhibitors and RT for breast cancer with @matteolambe, Philip Poortmans, Babara Pistilli and Gustavo Nader Marta.@OncoAlert @Dr_m_garousi @MartaPerachino @FatjonaKrajaMD @ChelainG @FrancicaPaola @Icro_Meattini #FlorenceBreast23 (@acampsmalea)

In this interview by @VJOncology I share a summary of the findings presented at #ASCO23 about the academic #NeoRhea trial - neoadjuvant palbociclib + ET for early ER+/HER2-neg #breastcancer https://t.co/2KtmdkZGmo (@ElisaAgostinett)

Some highlights from #ASCO23 on #breastcancer studies on CDK4/6 inhibitors: results from NATALEE, monarchE, and PENELOPE-B Published by @VJOncology https://t.co/9wnOih9BJa (@ElisaAgostinett)

This figure shows the substantial differences in baseline risk in the 4 trials of adjuvant CDK4/6 inhibitors in ER+ breast cancer. iDFS data for the control arms (ET, only). And by design, as several trials sought to enrich for high risk tumors. Via @DrHBurstein #breastcancer (@efrenbolivar)

This graph will go down in #bcsm history comparing the control arms of cdk4/6 inh trials to understand trial population risk. Hence why cross-trial outcomes can vary so greatly & extra caution is required to blame diff in efficacy on drugs vs trial risk popul +/-diff studydesign (@NicoleKuderer)

It’s really a shame if @AnthemBCBS is not approving ribociclib for 1st line metastatic ER+HER2- breast cancer. (@FelipeBatalini)

Waiting for similar invitation about commentary on routine use of upfront CDK 4/6 inhibitors in metastatic breast cancer (@sarojniraula)

The added cost of prolonged CDK4/6 inhibition is an issue that will continue to evolve. 'I think we need to better understand which patient population would benefit versus not.' @maryam_lustberg @YaleBreast #bcsm https://t.co/vnPXOUkbo8 @SmilowCancer @YaleMed @YNHH (@YaleCancer)

🩺 ASCO 2023 Breast Cancer 🎉 ➡️ What differences in the incidence of adverse events between younger and older patients receiving abemaciclib and endocrine therapy in the #monarchE trial? @ErikaHamilton9 @SarahCannonDocs #BreastCancer #ASCO23 🔗 https://t.co/x1gNrB6OvJ (@oncologytube)